COVID-19 vaccine of US company Novavax shows 89.3 pc efficacy in phase 3 trial in UK

Maryland [US], January 29 (ANI/Sputnik): The coronavirus vaccine developed by the US company Novavax has demonstrated 89.3 per cent efficacy during the phase 3 trials conducted in the United Kingdom, the company said in a statement.“Novavax, Inc, a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3 per cent, in its Phase 3 clinical trial conducted in the United Kingdom (UK),” the company said in a statement on late Thursday.In July,…